ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat ...
Westside Current on MSN4d
Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other ...
SAN FRANCISCO and SUZHOU, China, Sept. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
The Nation Newspaper4d
Shinkafi-Bagudu bags dicey Scroggins distinguished advocate award
Medicaid cancer foundation, on behalf of the International Gynecologic Cancer Society (IGCS), has announced that Dr. Zainab ...
Investor's Business Daily on MSN5d
Merck Scores Two Key Victories With Keytruda In Women's Cancers
Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies
Management will discuss the advantages of the Company’s 3S TCRs across a wide range of modalities, including TCR-engineered T cell (TCR-T) therapies, TCR-guided T cell engager therapies (TCR-TCE), and ...